Related Experiment Video
Updated: Mar 10, 2026
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
Dystonia in Methylphenidate Withdrawal: A Case Report.
Lara Grau-López1, Constanza Daigre, Nestor Mercado
1Addiction and Dual Diagnosis Unit Vall Hebron, ASPB, Department of Psychiatry, University Hospital Vall d'Hebron, CIBERSAM (LG-L, CD, MC, CR); Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain (LG-L, CD, MC, CR); and Department of Psychiatry, University Psychiatry Clinic, Universidad de Chile, Santiago, Chile (NM).
Dystonia, a movement disorder, can manifest as a rare withdrawal symptom during methylphenidate detoxification. This case highlights the need for clinicians to recognize and manage movement disorders during stimulant withdrawal.
Area of Science:
- Neuroscience
- Psychiatry
- Clinical Pharmacology
Background:
- Psychostimulant medications, like methylphenidate, are widely used for conditions such as ADHD.
- Withdrawal from psychostimulants can present with various symptoms, but movement disorders are infrequently reported.
Observation:
- A case of adult methylphenidate dependence undergoing inpatient detoxification is presented.
- The primary and most significant withdrawal symptom observed was dystonia, a type of movement disorder.
Findings:
- This report details the first known instance of dystonia as a principal withdrawal symptom following methylphenidate cessation.
- Movement disorders, including dystonia, are exceedingly rare adverse effects associated with methylphenidate withdrawal.
Implications:
- Clinicians should maintain a high index of suspicion for movement disorders during methylphenidate detoxification.
- Early recognition and management of dystonia are crucial for patients undergoing psychostimulant withdrawal to ensure appropriate care.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:30Toxidromes: Clinical Features
01:21Skeletal Muscle Relaxants: Adverse Effects
Unlike...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...